Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?

CAR-T cells therapy can give rise to most common and concerning two side effects – cytokine release syndrome (CRS) and neurotoxicity. But in our CD19 CAR-T cells therapy clinical trial, we observed 1 out of 17 patients with B-cell acute lymphoblastic leukemia (B-ALL) developed acute myelofibrosis(AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Xun, Sun, Yun Yan, Chang, Lung Ji, Ma, Yu Ru, Gu, Xue Zhong, Yao, Xiang Mei, Nie, Bo, Wen, Yan, Zhang, Xue Mei, Jiang, Ya Xian, Yang, Hui, Yu, Li Qun, Fang, Ming Jing, Wang, Ling, Yuan Bo, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291836/
https://www.ncbi.nlm.nih.gov/pubmed/32772769
http://dx.doi.org/10.1080/21655979.2020.1791597
Descripción
Sumario:CAR-T cells therapy can give rise to most common and concerning two side effects – cytokine release syndrome (CRS) and neurotoxicity. But in our CD19 CAR-T cells therapy clinical trial, we observed 1 out of 17 patients with B-cell acute lymphoblastic leukemia (B-ALL) developed acute myelofibrosis(AMF) after grade IV CRS post to the CD19 CAR-T cells therapy. This finding suggests that the CAR-T cells therapy may have rare and serious AMF, which we should pay important attention to. Trial registration:NCT02968472. Registered 18 November 2016 – Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02968472

Ejemplares similares